Stevens Capital Management LP Argenx Se Transaction History

Stevens Capital Management LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 06, 2020	SELL	$106.59 - $164.21 $265,195 - $408,554	-2,488 Closed	0 $0
Q3 2019 Nov 08, 2019	BUY	$113.31 - $150.51 $281,915 - $374,468	2,488 New	2,488 $284,000
Q4 2018 Feb 06, 2019	SELL	$63.81 - $109.82 $179,816 - $309,472	-2,818 Closed	0 $0
Q3 2018 Nov 13, 2018	BUY	$75.5 - $96.63 $212,759 - $272,303	2,818 New	2,818 $214,000

435

29.2M

390K

272K

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $34B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

Get notified when there are updates to the investment portfolio of Stevens Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Stevens Capital Management LP with notifications on news.